Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Biomarkers in Neuropsychiatry is Scopus-indexed (Q2, CiteScore 3.9), DOAJ. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 2666-1446Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biochemistry (medical) | 33 / 78 | 58th | Q2 |
| Psychiatry and Mental Health | 250 / 580 | 56th | Q2 |
| Neurology (clinical) | 197 / 403 | 51st | Q2 |
| Clinical Biochemistry | 71 / 124 | 43rd | Q3 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q2, CiteScore 3.9.
Biomarkers in Neuropsychiatry is Q2 in Biochemistry (medical) (rank 33 of 78), Q2 in Psychiatry and Mental Health (rank 250 of 580) and Q2 in Neurology (clinical) (rank 197 of 403), by CiteScore 2025. It is ranked in 4 subject areas in all.
Biomarkers in Neuropsychiatry is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 3.9, quartile Q2, 58th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.795, quartile Q2, with an H-index of 17.
The publisher lists an article processing charge of about US$2,930 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Biomarkers in Neuropsychiatry is published by Elsevier B.V. Its ISSN is 2666-1446.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Biomarkers in Neuropsychiatry has an h-index of 21 and a 2-year mean of 3.11 citations per paper (OpenAlex). Its Scopus CiteScore is 3.9, quartile Q2. On 2-year citations it ranks #22 of 77 Scopus journals in Biochemistry (medical).
Biomarkers in Neuropsychiatry published 16 papers in 2025; its busiest recent year was 2023 with 43. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2021–2026), authors are most often from United States (51.7%), Germany (7.8%) and United Kingdom (5.3%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.